Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-301: enfortumab vedotin versus chemotherapy in previously treated advanced or metastatic urothelial cancer
NL-OMON52767Phase 3Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Feb 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of enfortumab vedotin in transitional cell carcinoma (TCC) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Overall survival. Started Feb 2019; status: active, not recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON52767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52767.